- Trials with a EudraCT protocol (236)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
236 result(s) found for: Krebs Cycle.
Displaying page 1 of 12.
EudraCT Number: 2013-000799-14 | Sponsor Protocol Number: 0080CA002 | Start Date*: 2015-01-16 | |||||||||||
Sponsor Name:Novalon S. A. | |||||||||||||
Full Title: Phase III, open-label, multi-center study to assess the pharmacodynamic (PD), pharmacokinetic (PK) and safety of Zoreline 10.8 mg goserelin subcutaneous implant (Novalon) in male patients with pros... | |||||||||||||
Medical condition: Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: BE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005106-25 | Sponsor Protocol Number: D8241C00001 | Start Date*: 2021-11-15 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients with Advanced... | |||||||||||||
Medical condition: Advanced Haematological Malignancies | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003731-20 | Sponsor Protocol Number: CEGF816X2201C | Start Date*: 2015-05-19 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult... | |||||||||||||
Medical condition: EGFR mutated non-small cell lung cancer and EGFR wild-type non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Completed) NL (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005251-39 | Sponsor Protocol Number: PM1183-C-004-14 | Start Date*: 2015-06-15 | ||||||||||||||||
Sponsor Name:Pharma Mar S.A., Sociedad Unipersonal | ||||||||||||||||||
Full Title: Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) versus Pegylated Liposomal Doxorubicin or Topotecan in Patients with Platinum-resistant Ovarian Cancer (CORAIL Trial) | ||||||||||||||||||
Medical condition: Platinum-resistant ovarian cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: HU (Completed) ES (Completed) CZ (Completed) AT (Completed) BE (Completed) GB (Completed) FR (Completed) DE (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-001432-31 | Sponsor Protocol Number: CA190001 | Start Date*: 2008-04-11 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 1/2a, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects with Advanced Cancer. Revised Protocol 02, incorporating Protocol Amend... | |||||||||||||
Medical condition: Advanced Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006246-33 | Sponsor Protocol Number: LTS12674 | Start Date*: 2012-06-28 | |||||||||||
Sponsor Name:Sanofi-aventis recherche et développement | |||||||||||||
Full Title: International, Multi-Center, Open-label, Treatment Extension Study of Iniparib as Monotherapy or in Combination Chemotherapeutic Regimens in Cancer Patients Who Have Derived Clinical Benefit From I... | |||||||||||||
Medical condition: Solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001175-31 | Sponsor Protocol Number: ALM201/0001 | Start Date*: 2014-10-10 | ||||||||||||||||
Sponsor Name:Almac Discovery | ||||||||||||||||||
Full Title: A phase I open-label multicentre dose-escalation study of subcutaneous ALM201 in patients with advanced ovarian cancer and other solid tumours. | ||||||||||||||||||
Medical condition: Advanced ovarian cancer and other solid tumours | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004532-58 | Sponsor Protocol Number: LA-EP06-301 | Start Date*: 2012-08-20 | |||||||||||
Sponsor Name:Sandoz GmbH | |||||||||||||
Full Title: A randomized, double-blind, parallel-group, multi-center Phase 3 comparative study investigating efficacy and safety of LA-EP2006 and Neulasta® in breast cancer patients treated with myelosuppressi... | |||||||||||||
Medical condition: Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003883-31 | Sponsor Protocol Number: GEICO-1205 | Start Date*: 2013-04-02 | |||||||||||
Sponsor Name:Grupo Español de Investigación en Cáncer de Ovario | |||||||||||||
Full Title: A randomized phase II multi-centric open label clinical trial to determine the efficacy and toxicity of preoperative chemotherapy with or without bevacizumab in patients with advanced Ovarian Cancer. | |||||||||||||
Medical condition: Advanced Ovarian Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001144-22 | Sponsor Protocol Number: ML28337 | Start Date*: 2012-07-03 | |||||||||||||||||||||
Sponsor Name:ROCHE SAS | |||||||||||||||||||||||
Full Title: A RANDOMIZED, OPEN-LABEL, PHASE II STUDY ASSESSING THE EFFICACY AND THE SAFETY OF BEVACIZUMAB IN NEOADJUVANT THERAPY IN PATIENTS WITH FIGO STAGE IIIC/IV OVARIAN, TUBAL OR PERITONEAL ADENOCARCINOMA,... | |||||||||||||||||||||||
Medical condition: Epithelial ovarian cancer Fallopian tube carcinoma Primary peritoneal carcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004446-17 | Sponsor Protocol Number: MEDEA001 | Start Date*: 2012-03-13 | |||||||||||
Sponsor Name:VU University Medical Center Amsterdam | |||||||||||||
Full Title: Metoclopramide, dexamethasone or Aloxi for the prevention of delayed chemotherapy-induced nausea and vomiting in moderately emetogenic non-AC-based chemotherapy: the MEDEA trial | |||||||||||||
Medical condition: Patients with cancer receiving moderately emetogenic non-AC-based chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000441-41 | Sponsor Protocol Number: NB-ND021(NM21-1480)-101 | Start Date*: 2021-10-26 | |||||||||||
Sponsor Name:Numab Therapeutics AG | |||||||||||||
Full Title: A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients with Advanced Solid Tumors | |||||||||||||
Medical condition: Advanced Solid Tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001433-34 | Sponsor Protocol Number: CA190002 | Start Date*: 2008-03-14 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects with Advanced Cancer. Revised Protocol 04, incorporating Protocol Amendme... | |||||||||||||
Medical condition: Advanced cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002330-23 | Sponsor Protocol Number: 9794 | Start Date*: 2017-11-24 | |||||||||||
Sponsor Name:University hospital of Montpellier | |||||||||||||
Full Title: HEPATIC ARTERIAL INFUSION OF GEMCITABINE-OXALIPLATIN FOR SECOND-LINE THERAPY IN NON-METASTATIC UNRESECTABLE INTRA-HEPATIC CHOLANGIOCARCINOMA: A MULTICENTRIC SINGLE-ARM PHASE II STUDY | |||||||||||||
Medical condition: The combination of gemcitabine and oxaliplatin intra-arterial as second-line therapy can greatly improve the Objective Response Disorder (ORT) at 4 months | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000618-13 | Sponsor Protocol Number: BeTo-Ovar | Start Date*: 2019-05-10 | |||||||||||
Sponsor Name:Vejle Hospital | |||||||||||||
Full Title: Bevacizumab and tocotrienol in recurrent ovarian cancer. A marker based phase II trial | |||||||||||||
Medical condition: Ovarian cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001415-90 | Sponsor Protocol Number: MO42720 | Start Date*: 2022-12-12 | ||||||||||||||||
Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: INTERVENTIONAL PLATFORM STUDY INVESTIGATING THE IMPACT OF DIGITAL HEALTH SOLUTIONS ON HEALTH OUTCOMES AND HEALTH-CARE RESOURCE UTILIZATION IN PARTICIPANTS RECEIVING SYSTEMIC TREATMENT IN CLINICAL P... | ||||||||||||||||||
Medical condition: Cohort A: ●Metastatic non-small cell lung carcinoma (mNSCLC) ●Extensive-stage small-cell lung carcinoma (ES-SCLC) ●Advanced or unresectable hepatocellular carcinoma (HCC) Cohort B: Resected Stag... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) AT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004108-73 | Sponsor Protocol Number: D5082C00003 | Start Date*: 2018-03-05 | |||||||||||
Sponsor Name:AstraZeneca | |||||||||||||
Full Title: A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib versus Sunitinib in Patients with MET-Driven, Unresectable and Locally Advanced,... | |||||||||||||
Medical condition: papillary renal cell carcinoma (PRCC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002934-35 | Sponsor Protocol Number: ADVL1615 | Start Date*: 2021-05-21 | |||||||||||
Sponsor Name:Children's Oncology Group | |||||||||||||
Full Title: A Phase 1 Study of Pevonedistat (MLN4924, IND# 136078) a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory ... | |||||||||||||
Medical condition: This trial studies the side effects and best dose of pevonedistat when given together with irinotecan and temozolomide in treating patients with solid tumors or lymphoma that have come back after a... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024481-22 | Sponsor Protocol Number: EP06-302 | Start Date*: 2012-01-17 | |||||||||||
Sponsor Name:Sandoz GmbH | |||||||||||||
Full Title: A randomized, double-blind, parallel-group, multi-center Phase III study comparing the efficacy and safety of EP2006 and Neupogen® in breast cancer patients treated with myelosuppressive chemothe... | |||||||||||||
Medical condition: Breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) SK (Completed) LT (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005458-27 | Sponsor Protocol Number: MK-4830-002 | Start Date*: 2022-04-28 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Randomized, Phase 2 Study of Pembrolizumab And Chemotherapy With or Without MK-4830 as Neoadjuvant Treatment for High-Grade Serous Ovarian Cancer | |||||||||||||
Medical condition: First-line treatment of advanced High Grade Serous Ovarian Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.